Enteric coatings use materials that remain intact in acidic stomach conditions. As the dosage form moves into the small intestine, where pH is higher, the coating dissolves and permits the medication to be released. This pH-dependent behavior helps shift delivery away from the stomach and toward an intestinal site when formulation performance depends on that location.
Protective barriers and timed-release systems provide alternatives to a pH-triggered coating. A barrier can shield the medication during transit, whereas a timed design postpones release according to the system’s release schedule. These approaches broaden formulation options when delivery goals cannot be met solely by relying on the contrast between acidic stomach conditions and the higher pH of the small intestine.
Release timing can protect acid-sensitive drugs from degradation before they reach the intended intestinal region. It may also reduce direct exposure of the stomach to medicines that cause gastric irritation. These effects connect formulation behavior with both chemical stability and clinical tolerability, making release location a central design consideration.
During oral drug development, teams can evaluate whether an enteric coating, pH-sensitive polymer, protective barrier, or timed-release system best matches the intended release pattern. Formulation design must account for the desired gastrointestinal region and the medication’s sensitivity to stomach conditions. This assessment links dosage-form selection with expected treatment performance and tolerability.
They may be considered when oral treatment would benefit from intestinal rather than gastric delivery, when a drug is vulnerable to acid-related degradation, or when reducing gastric irritation is important. In these settings, delayed release supports a clinical strategy that aligns the dosage form with the desired delivery region and patient tolerability goals.
By postponing medication release, the formulation changes when the drug becomes available along the gastrointestinal tract rather than exposing it immediately in the stomach. That timing is relevant to pharmacokinetic assessment, because release location and schedule are formulation variables. It also supports patient-centered dosing strategies when treatment goals include improved tolerability or appropriately targeted intestinal delivery.